Introduction {#section5-1756284819881304}
============

Inflammatory bowel disease (IBD) is a group of gastrointestinal disorders represented by Crohn's disease (CD) and ulcerative colitis (UC), with a worldwide prevalence surpassing 0.3%.^[@bibr1-1756284819881304]^ Alternating periods of relapse and remission lead to a poor quality of life and require long-term pharmacological or surgical intervention.^[@bibr2-1756284819881304]^ Despite the availability of novel drugs, optimal therapy completely eliminating the symptoms of IBD is lacking, and future research aimed to elucidate underlying causes and to develop novel therapeutic options is needed. A number of hereditary, environmental and microbial factors seem to be linked with the development of IBD; however, the pathogenesis of disease remains to be clarified.^[@bibr3-1756284819881304][@bibr4-1756284819881304]--[@bibr5-1756284819881304]^ Epidemiological and clinical studies suggest a strong correlation of IBD with genetic predisposition and indicate its polygenic nature.^[@bibr6-1756284819881304]^ More than 230 disease loci, associated mainly with microbiological defence mechanisms, autophagy and immune response, were related with IBD, yet they account for only 20--25% of the heritability.^[@bibr4-1756284819881304],[@bibr6-1756284819881304]^ Accumulating data suggest that a complex interaction of genetic defects with other factors including lifestyle, diet, environmental pollution or disturbed intestinal microbiota, play a substantial role in the pathogenesis of IBD.^[@bibr4-1756284819881304],[@bibr6-1756284819881304],[@bibr7-1756284819881304]^

Metabolic degradation of tryptophan (TRP), an essential neutral amino acid, leads to biosynthesis of several neuroactive and immunoactive molecules. The kynurenine (KYN) pathway, which provides \>90% of TRP metabolism in mammals, is an important source of substances regulating the immune response.^[@bibr8-1756284819881304]^ Anti-inflammatory and cytoprotective compounds such as kynurenic acid (KYNA), as well as metabolites acting in a proinflammatory manner, generating free radicals or acting in a directly cytotoxic manner, such as 3-hydroxykynurenine (3-OH-KYN) and quinolinic acid (QUIN), are produced along two separate arms of the KYN pathway.^[@bibr8-1756284819881304]^

KYNA is the most pleiotropic molecule among TRP metabolites. As a broad-spectrum antagonist of glutamate receptors, displaying high affinity for the glycine site of the *N*-methyl-d-aspartate complex, KYNA was shown to counteract cytotoxicity in various experimental paradigms.^[@bibr9-1756284819881304]^ Furthermore, KYNA as an endogenous ligand of the aryl hydrocarbon receptor (AhR) and G-protein-coupled receptor 35 (GPR35), can display anti-inflammatory actions.^[@bibr8-1756284819881304],[@bibr9-1756284819881304]^ Peripheral KYNA is produced enzymatically, mostly, although not exclusively, in the process of transamination of KYN by aminotransferases (KATs) I--IV.^[@bibr10-1756284819881304],[@bibr11-1756284819881304]^ In the periphery, synthesis of KYNA occurs in a variety of cells and tissues, including endothelial and epithelial cells, fibroblasts, leukocytes, erythrocytes or myocytes.^[@bibr12-1756284819881304],[@bibr13-1756284819881304]^

Recent studies implicate the altered KYN pathway in the pathogenesis of IBD^[@bibr14-1756284819881304],[@bibr15-1756284819881304]^ The contribution of KYNA to intestinal mucosal defence, as well as its role in the modulation of intestinal motility and the inflammatory response were postulated.^[@bibr16-1756284819881304],[@bibr17-1756284819881304]^ The status of TRP metabolism and KYNA in IBD has been the subject of a few studies performed on small and large cohorts, but the available data are not conclusive. An increased serum level of KYNA in patients with IBD,^[@bibr14-1756284819881304]^ a positive correlation of the KYNA/TRP ratio with severity of inflammation in CD^[@bibr18-1756284819881304]^ as well as low serum TRP in IBD and reduced KYNA in patients with CD ^[@bibr19-1756284819881304]^ were demonstrated. Considering the inflammatory nature of IBD, the function of immunocompetent cells, including lymphocytes, has been intensively examined in the specimens obtained from patients with IBD. However, although it is generally accepted that IBD is as a systemic autoimmune disorder,^[@bibr20-1756284819881304]^ relatively less is known about the changes in peripheral population of lymphocytes in the course of disease. Furthermore, acquisition of blood samples in contrast to biopsy specimens is simple, low-cost and an almost stress-free procedure. Thus, we have aimed to study the specific aspects of KYN pathway metabolism in blood from the cohort of patients with IBD in comparison with healthy individuals. Considering that, up to our knowledge, there are no available data on the expression of mRNA encoding KAT I--III in IBD, we analysed the expression of KAT I \[glutamine transaminase K/cysteine conjugate β-lyase (CCBL1)\], KAT II \[aminoadipate aminotransferase (AADAT)\] and KAT III (CCBL2) in lymphocytes from patients with IBD. We also compared serum levels of four major TRP--KYN pathway metabolites in patients with CD or UC, during remission or relapse.

Materials and methods {#section6-1756284819881304}
=====================

Study population {#section7-1756284819881304}
----------------

A total of 55 patients with IBD and 35 healthy individuals were enrolled in the study between 2014 and 2016. Patients were recruited at the Gastroenterology Clinic of the Cardinal Stefan Wyszynński Voivodship Specialist Hospital in Lublin, Poland. The CD group (*n* = 27) included 13 females and 14 males (average age = 34.7 ± 11.19 years), and the UC group (*n* = 28) included 16 females and 12 males (average age = 36.9 ± 15.50 years). The control group (*n* = 50; healthy volunteers), included 36 females and 14 males (average age = 40.88 ± 9.11). The individuals from the control group did not manifest any signs or symptoms of inflammation (C-reactive protein, \<5 mg/l; white blood cells, 4--10 × 10^3^/µl). Additional exclusion criteria were autoimmune disorders, metabolic diseases or any chronic diseases in the past or at present. Disease activity score (UC: partial Mayo score; CD: Crohn's disease activity index) was recorded for each patient. Demographic characteristics of patients with CD and UC is depicted in [Table 1](#table1-1756284819881304){ref-type="table"}.

###### 

Demographic characteristics of control participants and patients with UC and CD.

![](10.1177_1756284819881304-table1)

  -----------------------------------------------------------------------------------------------------------------------------------
  Variable                               CTR *n* = 50   UC *n* = 28              CD *n* = 27             Statistical comparisons
  -------------------------------------- -------------- ------------------------ ----------------------- ----------------------------
  **Age** (years)                        40.58 ± 9.11   36.9 ± 15.50             34.7 ± 11.19            s = 0.02^1^\
                                                                                                         UC *versus* CTR s = 0.106\
                                                                                                         CD *versus* CTR s = 0.068

  **Sex** (male/female)                  14/36          12/16                    14/13                   s = 0.073^2^

  **Disease duration** (years)           --             4.96 ± 4.69              6.68 ± 4.8              --

  **Disease phase** (active/remission)   **--**         18 active/10 remission   19 active/8 remission   --
  -----------------------------------------------------------------------------------------------------------------------------------

Data are presented as mean values ±standard deviation.

Kruskal--Wallis *H* test for multiple comparison; ^b^chi-squared test.

CD, Crohn's disease; CTR, control; UC, ulcerative colitis.

The study was carried out with the consent of the patients, according to a protocol approved by the Local Bioethics Committee in Lublin (KE-0254/179/2016).

Genetic analyses {#section8-1756284819881304}
----------------

Blood was collected from the patients with IBD and controls between 7.00 and 11.00 a.m. mRNA transcript levels were assessed in isolated lymphocytes, by TaqMan real-time polymerase chain reaction (PCR) and were compared with normal controls. Gene-specific probes (Hs00212039_m1 for *AADAT*, Hs00187858_m1 for *CCBL1*, Hs00219725_m1 for *KAT3*, and Hs99999905_m1 for *GAPDH*) were obtained from Applied Biosystems. Expression of the gene *GAPDH* was used as an endogenous control. The results were analysed using Expression Suite v. 1.0.3 software (Life Technologies). The gene expression value (RQ) of *AADAT, CCBL1* and *KAT3*, relative to the control value, was calculated by the formula RQ = 2^--ΔΔCt^.^[@bibr21-1756284819881304]^

Chromatographic analyses of TRP metabolites {#section9-1756284819881304}
-------------------------------------------

Serum KYNA, KYN and TRP levels were determined by the ultra-high-pressure liquid chromatography (UHPLC) method with fluorescence detection (KYNA) and ultraviolet (UV) detection (KYN, TRP) using Waters Acquity UHPLC system and Waters C18 analytical column, according to Zhao and colleagues^[@bibr22-1756284819881304]^ in modification. The mobile phase contained 20 mmol/l sodium acetate, 3 mmol/l zinc acetate and 7% acetonitrile, at a flow rate of 0.1 ml/min. Quantification of TRP and its metabolites was performed by a UV variable wavelength detector (KYN at 365 nm; TRP at 250 nm) and by a fluorescence detector (KYNA-344 nm excitation and 398 nm emission). The 3-OH-KYN levels were determined fluorometrically, using an electrochemical detector (potential of working electrode: +0.20 V; Coulochem III, ESA) as described before. The HPLC column (HR-80; 3 µm; C~18~ reverse-phase column; ESA) was perfused at 0.6 ml/min using a mobile phase consisting of 2% acetonitrile, 0.9% triethylamine, 0.59% phosphoric acid, 0.27 mM sodium ethylenediaminetetraacetic acid and 8.9 mM heptane sulfonic acid.

Statistical analyses {#section10-1756284819881304}
--------------------

The proportion of TRP to KYN, KYN to KYNA, KYN to 3-OH-KYN and KYNA to 3-OH-KYN was calculated for each sample and served for the further assessment of respective average ratios in the studied groups. Differences in the expression of genes, levels of serum TRP, KYN, KYNA, 3-OH-KYN and metabolites ratios between any two groups of the patients were evaluated by Mann--Whitney *U* test. Age and sex data were analysed by chi-squared and Kruskal--Wallis *H* tests. All of the analyses were performed with the use of the program, Statistica version 13.

Results {#section11-1756284819881304}
=======

Genetic analyses {#section12-1756284819881304}
----------------

KAT1 and KAT3 mRNA expression was clearly enhanced in lymphocytes from both groups of patients with IBD, in comparison with controls \[[Figure 1(a)](#fig1-1756284819881304){ref-type="fig"}; [Table 2](#table2-1756284819881304){ref-type="table"}\]. The expression was increased during the active phase of IBD as well as during remission \[[Figure 1(b)](#fig1-1756284819881304){ref-type="fig"}; [Table 3](#table3-1756284819881304){ref-type="table"}\]. KAT2 expression was higher among patients with UC, but not in the entire CD group \[[Figure 1(a)](#fig1-1756284819881304){ref-type="fig"}; [Table 2](#table2-1756284819881304){ref-type="table"}\]. When analysed in subsets, KAT2 expression was significantly increased in patients with CD with remission, but not during the active phase \[[Figure 1(b)](#fig1-1756284819881304){ref-type="fig"}; [Table 3](#table3-1756284819881304){ref-type="table"}\].

![The expression of mRNA for KAT1 (CCBL1), KAT2 (AADAT) and KAT3 in entire cohorts of patients with inflammatory bowel disease (upper panel) and in relapse/remission (lower panel).\
^\*^*p* \< 0.05 *versus* control, Mann--Whitney *U* test.](10.1177_1756284819881304-fig1){#fig1-1756284819881304}

###### 

Descriptive statistic of gene expression values in the entire cohorts of patients with inflammatory bowel disease depicted in [Figure 1](#fig1-1756284819881304){ref-type="fig"} (upper panel).

![](10.1177_1756284819881304-table2)

  Gene            Group     Mean        Standard deviation
  --------------- --------- ----------- --------------------
  logRQ *AADAT*   Control   −0.037417   0.386163
  logRQ *CCBL1*   Control   −0.176893   0.361618
  logRQ *KAT3*    Control   −0.295346   0.302771
  logRQ *AADAT*   UC        0.529143    0.536293
  logRQ *CCBL1*   UC        0.565643    0.489776
  logRQ *KAT3*    UC        0.407314    0.644565
  logRQ *AADAT*   CD        0.197536    0.522393
  logRQ *CCBL1*   CD        0.518931    0.444622
  logRQ *KAT3*    CD        0.358035    0.465991

CD, Crohn's disease; UC, ulcerative colitis.

###### 

Descriptive statistic of gene expression values in subsets relapse/remission among UC and CD patients depicted in [Figure 1](#fig1-1756284819881304){ref-type="fig"} (lower panel).

![](10.1177_1756284819881304-table3)

  Gene            Group     Mean        Standard deviation
  --------------- --------- ----------- --------------------
  logRQ *AADAT*   control   −0.037417   0.386163
  logRQ *CCBL1*   control   −0.176893   0.361618
  logRQ KAT3      control   −0.295346   0.302771
  logRQ *AADAT*   UC act    0.329474    0.522930
  logRQ *CCBL1*   UC act    0.441619    0.530181
  logRQ *KAT3*    UC act    0.337341    0.725785
  logRQ *AADAT*   UC rem    0.814384    0.442051
  logRQ *CCBL1*   UC rem    0.813690    0.283485
  logRQ *KAT3*    UC rem    0.547259    0.450270
  logRQ *AADAT*   CD act    0.120905    0.600389
  logRQ *CCBL1*   CD act    0.474365    0.505363
  logRQ *KAT3*    CD act    0.275101    0.528823
  logRQ *AADAT*   CD rem    0.360377    0.259126
  logRQ *CCBL1*   CD rem    0.608065    0.293896
  logRQ *KAT3*    CD rem    0.523903    0.255029

act, active; CD, Crohn's disease; rem, remission; UC, ulcerative colitis.

TRP metabolites {#section13-1756284819881304}
---------------

The analyses carried out in the entire groups of patients with UC and CD revealed a significant decrease in serum TRP level, but not in KYN, KYNA or 3-OH-KYN, in both forms of IBD in comparison with controls \[[Figure 2(a--d)](#fig2-1756284819881304){ref-type="fig"}; [Table 4](#table4-1756284819881304){ref-type="table"}\]. Studies in subsets of patients with IBD showed that the lower TRP concentration was evident only among patients during active phase, but not in remission \[[Figure 3(a)](#fig3-1756284819881304){ref-type="fig"}; [Table 5](#table5-1756284819881304){ref-type="table"}\]. There were no statistically significant differences in the levels of KYN and 3-OH-KYN between active/remission phases in both forms of IBD \[[Figure 3(b](#fig3-1756284819881304){ref-type="fig"}, [d](#fig3-1756284819881304){ref-type="fig"}); [Table 5](#table5-1756284819881304){ref-type="table"}\]. In contrast, the KYNA level was lower during remission of UC or CD in comparison with respective relapse, but not *versus* controls \[[Figure 3(c)](#fig3-1756284819881304){ref-type="fig"}; [Table 5](#table5-1756284819881304){ref-type="table"}\].

![Serum levels of TRP, KYN, KYNA and 3-OH-KYN in the entire cohorts of patients with UC or CD. (a) TRP, (b) KYN, (c) KYNA and (d) 3-OH-KYN.\
Data are shown as mean values ± standard deviation.\
^\*^*p* \< 0.05 *versus* control, Mann--Whitney *U* test.\
3-OH-KYN, 3-hydroxykynurenine; CD, Crohn's disease; KYN, kynurenine; KYNA, kynurenic acid; TRP, tryptophan; UC, ulcerative colitis.](10.1177_1756284819881304-fig2){#fig2-1756284819881304}

###### 

Descriptive statistic for examined variables in the entire cohorts of patients with inflammatory bowel disease depicted in [Figure 2](#fig2-1756284819881304){ref-type="fig"}.

![](10.1177_1756284819881304-table4)

  Variable               Group     Mean       Standard deviation
  ---------------------- --------- ---------- --------------------
  nmol TRP/1 ml          Control   48.09521   13.11105
  nmol KYN/1 ml          Control   2.89472    1.20331
  pmol KYNA/1 ml         Control   38.32564   6.01713
  pmol 3-OH-KYN/100 µl   Control   3.33292    1.82605
  nmol TRP/1 ml          UC        35.57201   11.12452
  nmol KYN/1 ml          UC        5.50331    5.15197
  pmol KYNA/1 ml         UC        38.07619   11.17509
  pmol 3-OH-KYN/100 µl   UC        4.03994    2.79404
  nmol TRP/1 ml          CD        37.83329   9.397528
  nmol KYN/1 ml          CD        8.36110    7.433653
  pmol KYNA/1 ml         CD        39.96442   9.110676
  pmol 3-OH-KYN/100 µl   CD        3.56931    2.073936

3-OH-KYN, 3-hydroxykynurenine; CD, Crohn's disease; KYN, kynurenine; KYNA, kynurenic acid; TRP, tryptophan; UC, ulcerative colitis.

![Serum levels of TRP, KYN, KYNA and 3-OH-KYN in active phase (act) *versus* remission (rem) subsets of patients with ulcerative colitis (UC) or Crohn's disease (CD). (a) TRP, (b) KYN, (c) KYNA and (d) 3-OH-KYN.\
Data are shown as mean values ± standard deviation.\
^\*^*p* \< 0.05 *versus* control, Mann--Whitney *U* test; ^a^*p* \< 0.05 *versus* respective remission.\
3-OH-KYN, 3-hydroxykynurenine; KYN, kynurenine; KYNA, kynurenic acid; TRP, tryptophan.](10.1177_1756284819881304-fig3){#fig3-1756284819881304}

###### 

Descriptive statistic for examined variables in active phase (act) *versus* remission (rem) subsets of patients with UC or CD depicted in [Figure 3](#fig3-1756284819881304){ref-type="fig"}.

![](10.1177_1756284819881304-table5)

  Variable                Group     Mean       Standard deviation
  ----------------------- --------- ---------- --------------------
  nmol TRP/1 ml           Control   48.09521   13.11105
  nmol KYN/1 ml           Control   2.89472    1.20331
  pmol KYNA/1 ml          Control   38.32564   6.01713
  pmol 3-OH-KYN/100 µl    Control   3.33292    1.82605
  nmol TRP/1 ml           UC act    32.63355   11.98789
  nmol KYN/1 ml           UC act    5.26213    5.42499
  pmol KYNA/1 ml          UC act    43.03806   10.65319
  pmol 3-OH-KYN/100 µl    UC act    3.80238    2.83063
  nmol TRP/1 ml           UC rem    41.77542   5.525099
  nmol KYN/1 ml           UC rem    6.07612    4.730355
  pmol KYNA/1 ml          UC rem    29.80641   6.109712
  pmol 3-OH-KYN/100 µl    UC rem    4.60414    2.806357
  nmol TRP/1 ml           CD act    36.89533   11.04814
  nmol KYN/1 ml           CD act    7.54809    8.26002
  pmol KYNA/1 ml          CD act    44.56571   5.52225
  pmol 3-OH-KYN /100 µl   CD act    2.89248    2.09946
  nmol TRP/1 ml           CD rem    39.44123   6.032050
  nmol KYN/1 ml           CD rem    9.75484    6.091381
  pmol KYNA/1 ml          CD rem    29.84158   6.979681
  pmol 3-OH-KYN /100 µl   CD rem    4.72959    1.528392

3-OH-KYN, 3-hydroxykynurenine; CD, Crohn's disease; KYN, kynurenine; KYNA, kynurenic acid; TRP, tryptophan; UC, ulcerative colitis.

Functional changes in TRP metabolism {#section14-1756284819881304}
------------------------------------

When analysed in the entire groups of patients with UC or CD, a significant decrease of TRP/KYN ratio was observed in comparison with controls \[[Figure 4(a)](#fig4-1756284819881304){ref-type="fig"}; [Table 6](#table6-1756284819881304){ref-type="table"}\]. KYN/KYNA and KYNA/3-OH-KYN ratios were not altered in both forms of IBD \[[Figure 4(b](#fig4-1756284819881304){ref-type="fig"}, [d](#fig4-1756284819881304){ref-type="fig"}); [Table 6](#table6-1756284819881304){ref-type="table"}\]. The ratio KYN/3-OH-KYN increased about two-fold among patients with CD \[[Figure 4(c)](#fig4-1756284819881304){ref-type="fig"}; [Table 6](#table6-1756284819881304){ref-type="table"}\].

![The ratios between metabolites of TRP in the entire cohorts of patients with ulcerative colitis (UC) or Crohn's disease (CD). (a) TRP/KYN, (b) KYN/KYNA, (c) KYN/3-OH-KYN and (d) KYNA/3-OH-KYN.\
Data are shown as mean values ± standard deviation.\
^\*^*p* \< 0.05 *versus* control, Mann--Whitney *U* test.\
3-OH-KYN, 3-hydroxykynurenine; KYN, kynurenine; KYNA, kynurenic acid; TRP, tryptophan.](10.1177_1756284819881304-fig4){#fig4-1756284819881304}

###### 

Descriptive statistic for examined variables in the entire cohorts of patients with inflammatory bowel disease depicted in [Figure 4](#fig4-1756284819881304){ref-type="fig"}.

![](10.1177_1756284819881304-table6)

  Variable (ratio)   Group     Mean       Standard deviation
  ------------------ --------- ---------- --------------------
  TRP/KYN            Control   20.97565   24.99752
  KYN/KYNA           Control   0.07759    0.03575
  KYN/3-OH-KYN       Control   1.23464    1.15304
  KYNA/3-OH-KYN      Control   16.48301   14.37523
  TRP/KYN            UC        12.40922   9.10632
  KYN/KYNA           UC        0.15581    0.15807
  KYN/3-OH-KYN       UC        2.01183    2.08659
  KYNA/3-OH-KYN      UC        15.09839   12.37899
  TRP/KYN            CD        12.40922   9.10632
  KYN/KYNA           CD        0.16920    0.15836
  KYN/3-OH-KYN       CD        2.99694    2.79473
  KYNA/3-OH-KYN      CD        20.24263   17.36052

3-OH-KYN, 3-hydroxykynurenine; CD, Crohn's disease; KYN, kynurenine; KYNA, kynurenic acid; TRP, tryptophan; UC, ulcerative colitis.

There was a decrease of TRP/KYN ratio in active phase of UC and among patients with CD in remission in comparison with control \[[Figure 5(a)](#fig5-1756284819881304){ref-type="fig"}; [Table 7](#table7-1756284819881304){ref-type="table"}\]. No significant difference between relapse and remission for any of the analysed ratios, apart from an increase of KYNA/3-OH-KYN ratio in the active phase of CD in comparison with CD remission was observed \[[Figure 5(b--d)](#fig5-1756284819881304){ref-type="fig"}; [Table 7](#table7-1756284819881304){ref-type="table"}\].

![The ratios between metabolites of TRP in active phase (act) *versus* remission (rem) subsets of patients with ulcerative colitis (UC) or Crohn's disease (CD). (a) TRP/KYN, (b) KYN/KYNA, (c) KYN/3-OH-KYN and (d) KYNA/3-OH-KYN.\
Data are shown as mean values ± standard deviation.\
^\*^*p* \< 0.05 *versus* control, ^a^*p* \< 0.05 *versus* respective remission; Mann--Whitney *U* test.\
3-OH-KYN, 3-hydroxykynurenine; KYN, kynurenine; KYNA, kynurenic acid; TRP, tryptophan.](10.1177_1756284819881304-fig5){#fig5-1756284819881304}

###### 

Descriptive statistic for the examined variables in active phase (act) *versus* remission (rem) subsets of patients with UC or CD depicted in [Figure 5](#fig5-1756284819881304){ref-type="fig"}.

![](10.1177_1756284819881304-table7)

  Variable              Group     Mean       Standard deviation
  --------------------- --------- ---------- --------------------
  Ratio TRP/KYN         Control   20.97565   24.99752
  Ratio KYN/KYNA        Control   0.07759    0.03575
  Ratio KYN/3-OH-KYN    Control   1.23464    1.15304
  Ratio KYNA/3-OH-KYN   Control   16.48301   14.37523
  Ratio TRP/KYN         UC act    12.40523   9.55234
  Ratio KYN/KYNA        UC act    0.12830    0.14983
  Ratio KYN/3-OH-KYN    UC act    2.14093    2.35894
  Ratio KYNA/3-OH-KYN   UC act    17.58799   13.93756
  Ratio TRP/KYN         UC rem    12.41870   8.565722
  Ratio KYN/KYNA        UC rem    0.20740    0.170197
  Ratio KYN/3-OH-KYN    UC rem    1.70524    1.307593
  Ratio KYNA/3-OH-KYN   UC rem    10.43040   7.410389
  Ratio TRP/KYN         CR act    10.68468   7.98902
  Ratio KYN/KYNA        CR act    0.12853    0.12342
  Ratio KYN/3-OH-KYN    CR act    3.43799    3.18422
  Ratio KYNA/3-OH-KYN   CR act    26.48682   17.64786
  Ratio TRP/KYN         CR rem    7.651920   8.480039
  Ratio LKYN/KYNA       CR rem    0.258654   0.203501
  Ratio KYN/3-OH-KYN    CR rem    2.240854   1.945990
  Ratio KYNA/3-OH-KYN   CR rem    6.505416   2.911304

3-OH-KYN, 3-hydroxykynurenine; CD, Crohn's disease; KYN, kynurenine; KYNA, kynurenic acid; TRP, tryptophan; UC, ulcerative colitis.

Discussion {#section15-1756284819881304}
==========

In the population of patients with IBD, the expression of KAT1 and KAT3 mRNA in the lymphocytes was higher in comparison with healthy controls, and expression did not seem to be associated with the clinical phase of disease. Enhanced expression was noted in the entire cohorts of patients with UC and CD, as well as in the relapse/remission subsets. Expression of KAT2 mRNA was enhanced in the cohort of UC and in patients with CD during remission. Such upregulation of KYNA biosynthetic enzymes can be viewed either as a compensatory response to ongoing inflammation or a primary abnormality. Further analyses were aimed to establish whether enhanced expression of KATs mRNA was indeed followed by changes in TRP metabolites.

Concomitant evaluation of KYNA and related substances, that is, TRP itself, KYN, a direct KYNA precursor, and 3-OH-KYN, a second metabolite of KYN along another metabolic arm, revealed depletion of TRP but no change in other metabolites in the entire cohorts of UC and CD. This is in agreement with previous reports demonstrating a deficiency of TRP in IBD.^[@bibr18-1756284819881304],[@bibr19-1756284819881304],[@bibr23-1756284819881304]^ We also observed significantly reduced TRP levels among both groups of patients with IBD during relapse, but not in remission.

The activity of rate-limiting enzyme, indoleamine 2,3-dioxygenase (IDO), catabolizing TRP to KYN, is tightly regulated by proinflammatory molecules, and an enhanced expression of IDO in the intestinal mucosa of patients with IBD was shown previously.^[@bibr24-1756284819881304],[@bibr25-1756284819881304]^ Thus, it is conceivable that the depletion of serum TRP results from an enhanced conversion to KYN. Indeed, we noted a significant decrease of the TRP/KYN ratio in patients with UC and CD, although serum KYN remained unchanged. A significant reduction in TRP availability combined with enhanced metabolic conversion of KYN to downstream products, may represent a possible explanation for this finding. Similarly, unchanged KYN levels were reported in patients with CD.^[@bibr18-1756284819881304]^ However, others showed elevated serum KYN among patients with IBD.^[@bibr14-1756284819881304],[@bibr24-1756284819881304]^ In our set of data, a trend for an increase in KYN was observed, but, due to a relatively low number of enrolled patients and high variability, the effect was not statistically significant.

Accumulating evidence indicates that availability of TRP plays a crucial role in the regulation of the immune response, notably as a counter-regulatory mechanism in inflammation.^[@bibr8-1756284819881304]^ Mice fed a low-TRP diet were more susceptible to chemically induced inflammation, whereas a sufficient amount of TRP in the diet reduced inflammation and decreased the severity of colitis.^[@bibr25-1756284819881304],[@bibr26-1756284819881304]^ Similarly, colitis symptoms and production of intestinal inflammatory cytokines in AhR-deficient mice were suppressed by activation of AhR with a TRP-enriched diet.^[@bibr27-1756284819881304]^ Intensified conversion of TRP to KYNA along the KYN pathway has been implicated in the protective action of TRP in colitis. Such a scenario assumes that proinflammatory mediators produce a signal that simultaneously activates the mechanisms opposing inflammation. KYNA can mediate immunosuppressive effects, largely by targeting GPR35, abundantly expressed on enterocytes, or *via* AhR-associated signalling pathways.^[@bibr8-1756284819881304]^ KYNA was also shown to inhibit tumour necrosis factor-α production in peripheral blood mononuclear cells.^[@bibr28-1756284819881304]^ Indeed, KYNA administration reduced colon motility and inflammation in an experimental model of colitis.^[@bibr16-1756284819881304],[@bibr17-1756284819881304]^ Others, however, revealed that dietary TRP supplementation failed to improve the survival rate and to ameliorate the morphological parameters of experimental colitis in mice.^[@bibr29-1756284819881304]^

Interestingly, despite uniformly enhanced expression of KATs, the average serum level of KYNA in the entire cohorts of patients with UC and CD was unchanged. However, when studied in subgroups of patients, KYNA was significantly lower during relapse in patients with UC in comparison with controls, similarly to data presented by others.^[@bibr19-1756284819881304]^ Furthermore, in both, CD and UC subsets, KYNA was significantly lower during remission *versus* the respective active phase. There are two alternative explanations that may explain these observations. First, an increased expression of KATs may be either genetically determined or can reflect the activation of the KYN pathway by proinflammatory molecules released during an active systemic autoimmune process. It is conceivable that observed fluctuations in TRP and KYNA levels between relapse and remission in IBD mirror the existence of yet unidentified factor(s) directly regulating KYNA synthesis. Our reported decrease of serum KYNA during relapse in patients with UC and CD partially agrees with the data presented in an elegant study by Nikolaus and colleagues, concerning TRP and other kynurenines and performed on a large cohort of patients with IBD.^[@bibr19-1756284819881304]^ A decrease in the serum KYNA level was observed among patients with CD but not those with UC in comparison with healthy controls.^[@bibr19-1756284819881304]^ Ascribing this difference to the number of studied participants cannot be ruled out but this does not seem highly probable, considering that, similarly to others,^[@bibr19-1756284819881304]^ we have found a decrease in TRP levels in patients with CD and UC, as well as lower TRP/KYN ratios. The nature of such a discrepancy is therefore, not clear and comparing the data on KATs mRNA expression could shed some light on this; however, to our knowledge, this issue has not been studied so far.

As mentioned above, our observation on decreased TRP levels in IBD is in agreement with other reports, performed in smaller and larger cohorts of patients and showing that depletion of TRP is linked with the relapse in IBD.^[@bibr6-1756284819881304],[@bibr19-1756284819881304]^ Furthermore, the successful biological therapy evokes a sustained increase in TRP.^[@bibr19-1756284819881304]^ It is tempting to explain our observation of enhanced KAT expression, as a regulatory, protective mechanism; the onset of acute inflammation resulting from exacerbation of IBD initiates a sequel of events starting from activation of IDO, followed by the immediate conversion of produced TRP to KYN, as well as activation of KATs, yet without a net increase of KYNA. Indeed, it was shown previously that, for example, the tumour necrosis factor-α-evoked stimulation of KAT expression is not paralleled by an increase in KYNA synthesis.^[@bibr30-1756284819881304]^

Thus, permanently higher expression of *KAT* genes, together with a larger pool of KYNA substrate, KYN, would result in the functional boosting of the KYN pathway arm, leading to KYNA, and also in relatively weaker production of cytotoxic compounds along the other arm of the pathway. Indeed, we have observed an increase in the KYNA/3-OH-KYN ratio among a subset of patients with IBD during relapse. Prevailing KYNA could suppress cytotoxicity and inflammation and in this way restrict pathological events in IBD. This hypothesis requires further investigation and extended analyses are on the way. At present, we may only draw some conclusions based on scarce available literature, mostly concerning the effects of immune molecules on KAT expression in brain tissue.

In the rat brain, systemic lipopolysaccharide administration had no effect on KAT II expression.^[@bibr31-1756284819881304]^ In macrophage and microglia cells, there was no effect of interferon-γ treatment on KAT activity.^[@bibr32-1756284819881304]^ In human hippocampal progenitor cells, KAT I and KAT III, but not KAT II mRNA, were downregulated after interleukin-1β treatment.^[@bibr33-1756284819881304]^ Importantly, in the course of another autoimmune disorder, multiple sclerosis, a significant decrease of KYNA in cerebrospinal fluid occurs during remission, whereas it is increased in the cerebrospinal fluid and plasma of patients with multiple sclerosis undergoing acute clinical exacerbation.^[@bibr34-1756284819881304],[@bibr35-1756284819881304]^ It has been speculated that such changes in KYNA levels during disease progression and remission reflect a compensatory, protective mechanism against neurotoxicity. Thus, applying a similar pattern to IBD, one may hypothesize that during relapse, relatively stronger activity of the KYN pathway arm leading to KYNA is aimed to counteract inflammation and cytotoxicity. The nature of mechanisms underlying such regulation remains to be established and seems of great interest.

An alternative explanation arises from recent data implicating the composition of intestinal microbiota as the factor altering the host immune system and influencing TRP availability and metabolism.^[@bibr23-1756284819881304]^ The interactions are reciprocal and TRP and its metabolites of (1) alimentary origin, (2) produced by gut microbiota (indole, indolic acid, skatole, and tryptamine), and (3) endogenously synthesized (kynurenines, serotonin, and melatonin), may impact the microbial composition and the host--microbiome interaction.^[@bibr26-1756284819881304]^ Considering that enhanced expression of KATs was found in patients with IBD irrespective of disease activity, the dysbiotic microbiome could produce larger quantities of TRP, subsequently converted to KYN, during relapse. In fact, interleukin-10-deficient (IL-10^−/−^) mice, developing CD-like colitis when exposed to a pathogenic microbial environment, manifested elevated plasma KYN.^[@bibr36-1756284819881304]^ Conversely, restoration of intestinal levels of probiotic bacteria such as *Lactobacillus* sp., evoked a decrease in serum KYN in stressed mice.^[@bibr37-1756284819881304]^ Taken together, the data presented here support and extend previous findings on altered TRP metabolism in IBD.

Conclusion {#section16-1756284819881304}
==========

The presented data indicate that IBD is associated with an enhanced expression of genes encoding KYNA biosynthetic enzymes in lymphocytes; however, additional mechanisms appear to influence KYNA levels. Higher metabolic conversion of serum TRP in IBD seems to be followed by the functional shift of KYN pathway towards the arm producing KYNA during exacerbation. We propose that KYNA, possibly *via* interaction with the AhR or GPR35, may serve as a counter-regulatory mechanism, decreasing cytotoxicity and inflammation in IBD. Further longitudinal studies evaluating the individual dynamics of TRP and the KYN pathway in patients with IBD, as well as the nature of precise mechanisms regulating KYNA synthesis, should be helpful in better understanding the processes underlying observed changes.
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